ZURA stock forecast, quote, news & analysis
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need... Show more
Why Zura Bio (ZURA) Stock Is Down -16.8% in the Last 30 Days
Key Takeaways
- Zura Bio (ZURA) shares fell roughly 16.8% over the last 30 days, from a closing price of $4.04 on September 25, 2026 to $3.36 on October 23, 2026.
- The decline extends a broader pullback that has taken the clinical-stage immunology company from about $5.43 in late July to the low-$3 range.
- No single company-specific negative event drove the move; the pullback reflects typical pre-data volatility for a biotech without commercial revenue.
- Investor focus remains on the upcoming Phase 2 TibuSHIELD topline readout in hidradenitis suppurativa, expected in the fourth quarter of 2026.
- Zura ended Q2 2026 with approximately $205.1 million in cash and equivalents, which management expects to fund operations through at least the end of 2028.
- Analyst sentiment remains largely constructive, with a consensus Strong Buy rating and an average price target well above the current share price.
- For additional data on this ticker, explore the dedicated Price Targets, Earnings, and Forecast pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies across the market.
Zura Bio (ZURA) Company Overview and Market Position
Zura Bio Limited is a clinical-stage, multi-asset biotechnology company developing dual-pathway antibody therapies for autoimmune and inflammatory diseases with significant unmet need. Its lead candidate, tibulizumab (ZB-106), is a bispecific antibody designed to neutralize both interleukin-17 (IL-17) and B-cell activating factor (BAFF), two key mediators of inflammation and fibrosis.
Tibulizumab is being evaluated in two Phase 2 studies: TibuSHIELD in hidradenitis suppurativa (HS) and TibuSURE in systemic sclerosis (SSc). The company has also selected polymyalgia rheumatica as a third indication, with a Phase 2 study expected to initiate by the end of 2026. Zura's earlier-stage pipeline includes crebankitug (ZB-168) and torudokimab (ZB-880). Because the company generates no product revenue, investors follow ZURA primarily for its clinical catalysts and cash position rather than near-term profitability.
Zura Bio (ZURA) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ZURA declined approximately 16.8%, moving from a $4.04 close on September 25, 2026 to $3.36 on October 23, 2026. The slide was not linear: the stock briefly spiked in mid-October before giving back those gains and closing near its recent lows.
The quarterly picture is steeper. At the start of August 2026 the shares traded around $5.43, meaning the stock has shed roughly 38% over the trailing three months. This multi-month decline has brought ZURA toward the lower end of its 52-week range of $3.25 to $7.44, underscoring the pronounced volatility that characterizes pre-commercial biotech names ahead of binary data events.
What Drove ZURA Stock Price in the Last 30 Days
The 30-day decline does not appear to be tied to a single, company-specific negative announcement. Instead, the move reflects the dynamics common to clinical-stage biotechs approaching major readouts: profit-taking, elevated volatility, and position adjustments ahead of the Phase 2 TibuSHIELD topline data expected in the fourth quarter of 2026.
Rating actions were mixed during the period. Several sell-side firms reiterated bullish views, including Buy ratings from Guggenheim and Leerink Partners, while Piper Sandler maintained its Buy rating with a higher price target. At the same time, at least one quantitative rating service assigned a Sell designation, and one analyst downgrade was recorded over the past month, illustrating the range of opinions around the name. With no recurring revenue, the stock's valuation is driven almost entirely by sentiment around the pipeline, making it sensitive to shifts in risk appetite across the small-cap biotech sector.
What Drove ZURA Stock Performance Over the Last Quarter
Over the last quarter, ZURA transitioned from a period of relative strength into a sustained pullback. The shares reached intraday highs near $7 in late August 2026 before beginning a decline that carried through September and October. The broader narrative has been one of anticipation rather than fundamental deterioration.
In August, Zura reported second-quarter 2026 results, posting a wider net loss of $26.3 million driven by higher research and development spending, while confirming that enrollment had been completed in both the TibuSHIELD and TibuSURE studies. The company also announced plans to advance tibulizumab into a third indication, polymyalgia rheumatica. While these were generally viewed as positive execution milestones, the lack of near-term revenue and the pending binary data readouts left the stock exposed to the risk-off sentiment that weighed on pre-revenue biotech names during the period.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader platform that offers hundreds of automated strategies covering thousands of tickers. Only top-performing and most relevant bots appear in this section, and each bot differs in its trading strategy, timeframe, and performance metrics, giving users a view of the diverse approaches available. For traders interested in systematic, data-driven ways to monitor markets, the page offers a practical starting point to explore how AI-powered tools approach stock selection and trade timing.
ZURA Stock Forecast Drivers: What Investors Should Watch Next
The most significant upcoming catalyst for ZURA is the Phase 2 TibuSHIELD topline readout in hidradenitis suppurativa, expected during the fourth quarter of 2026. Results from the TibuSURE study in systemic sclerosis are anticipated in the first half of 2027, and the company plans to initiate its Phase 2 NEXUS-PMR study in polymyalgia rheumatica by year-end 2026.
Investors should also monitor quarterly earnings, which will continue to reflect a net loss and rising R&D expense as the clinical programs advance. Macroeconomic conditions and sector-level sentiment toward small-cap, pre-revenue biotech stocks remain important factors given ZURA's dependence on risk appetite. Finally, the company's cash position of roughly $205.1 million as of June 30, 2026, provides a runway into at least late 2028, reducing near-term financing risk but leaving clinical outcomes as the primary determinant of value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZURA's RSI Oscillator is remaining in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZURA advanced for three days, in 153 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ZURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In 51 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for ZURA turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 40 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ZURA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.989) is normal, around the industry mean (3.498). P/E Ratio (-3.652) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ZURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology